CRL vs VATE
CRL: A global contract research organization providing non-clinical drug development services, research models, and manufacturing solutions across discovery, safety assessment, and biologics testing. VATE: A diversified holding company actively restructuring its portfolio through the divestiture of its infrastructure and spectrum businesses to focus on long-term value creation.
Side-by-side fundamentals
| Metric | CRL | VATE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $218.70 | $8.05 | |
| Market cap as of 2026-07-23 | $10.6B | $116M | |
| PEG as of 2026-07-23 | -0.12 | -0.08 | CRL lower |
| Net margin as of 2026-07-23 | -4.6% | -4.0% | VATE higher |
| Gross margin as of 2026-07-23 | +34.5% | +15.5% | CRL higher |
| Operating margin as of 2026-07-23 | +1.8% | +2.6% | VATE higher |
| ROE as of 2026-07-23 | -5.7% | -7.1% | CRL higher |
| ROA as of 2026-07-23 | -2.5% | -5.7% | CRL higher |
| Debt / equity as of 2026-07-23 | 0.91 | 1.39 | CRL lower |
| Revenue growth (YoY) as of 2026-07-23 | +0.1% | +25.4% | VATE higher |
| Revenue CAGR (3y) SEC XBRL | +0.3% | -8.7% | CRL higher |
| Dividend yield as of 2026-07-23 | n/a | +2.0% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 1.38 | 2.35 | |
| 1-year return as of 2026-07-22 close | +33.9% | +44.0% | VATE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.